Prokidney Corp. ( (PROK) ) has released its Q2 earnings. Here is a breakdown of the information Prokidney Corp. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProKidney Corp. is a biotechnology company focused on developing treatments to preserve kidney function in patients with chronic kidney disease, operating primarily in the healthcare sector. In its latest earnings report for the quarter ended June 30, 2025, ProKidney Corp. reported a net loss of $36.97 million, compared to a net loss of $38.47 million in the same period last year. The company generated revenue of $221,000 for the quarter, marking a significant improvement from zero revenue in the previous year, primarily from leasing activities. Operating expenses decreased slightly to $39.93 million from $43.06 million, with research and development costs being the largest component. Despite the net loss, the company saw an increase in its cash and cash equivalents to $84.94 million, although this was a decrease from $99.12 million at the end of 2024. Looking ahead, ProKidney Corp. remains focused on advancing its clinical trials and exploring strategic opportunities to enhance shareholder value, while managing its financial resources prudently.